Biologic Therapies for Hidradenitis Suppurativa

EP: 1.Signs and Symptoms of Hidradenitis Suppurativa (HS)

EP: 2.Epidemiology and Impact of Hidradenitis Suppurativa

EP: 3.The Pathophysiology of Hidradenitis Suppurativa

EP: 4.Differential Diagnosis When Considering Hidradenitis Suppurativa in a Patient

EP: 5.Overview of the Hurley Staging System for Hidradenitis Suppurativa

EP: 6.Comorbidities and Coordinating Care Between Specialists in Hidradenitis Suppurativa

EP: 7.Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate

EP: 8.The Impact of Hidradenitis Suppurativa on Families

EP: 9.Hidradenitis Suppurativa (HS): Staging Considerations and Unmet Needs

EP: 10.The Role of Treatment Guidelines for HS

Now Viewing

EP: 11.Biologic Therapies for Hidradenitis Suppurativa

EP: 12.Recent Data on Bimekizumab for Hidradenitis Suppurativa

EP: 13.Ongoing Research in Hidradenitis Suppurativa

EP: 14.Managing Pain in Patients with Hidradenitis Suppurativa

EP: 15.The Role of Surgery in Hidradenitis Suppurativa

EP: 16.Optimizing Multidisciplinary Care of Patients with Hidradenitis Suppurativa

Video content above is prompted by the following questions:

• What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
• Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?